Bruker Corporation (BRKR) recently entered into a definitive share purchase agreement with TecFin S.à r.l., a controlled affiliate of the pre-eminent private equity firm PAI Partners, to acquire ELITechGroup. However, the €870 million cash transaction excludes the carved-out ELITech clinical chemistry business. The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals, the carve-out of the clinical chemistry business and other customary closing conditions. Upon clos ...